Founded in 2006 and based in Lebanon, New Hampshire, ImmuRx, Inc. is dedicated to developing innovative adjuvant platforms for the treatment of cancers and infectious diseases. The company's core mission is to enhance the effectiveness of immunotherapies through its proprietary CD40 compound, an antibody designed to reduce solid tumor mass, improve survival times in various tumor models, and offer protection against viral and bacterial infections. ImmuRx focuses on leveraging its advanced immunological research to address critical needs in oncology and infectious disease markets.

Notable figures affiliated with ImmuRx include leading immunologists and biotech investors who support the company's pioneering work. Key achievements of ImmuRx include demonstrating significant efficacy in preclinical models of both cutaneous and hematopoietic tumors, as well as in combating viral and bacterial infections. The company's impact is marked by its potential to revolutionize cancer treatment protocols and infectious disease management, contributing to improved patient outcomes and advancing the field of immunotherapy.